Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Sponsor:

PrECOG, LLC.

Code:

NCT06538038

Conditions

Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor Gene Mutation

Stage III Lung Cancer

Stage IV Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Osimertinib

Osimertinib + Chemotherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information